Skip to main content
SpringerLink
Log in

Efficacy of the Levonorgestrel-Releasing Intrauterine System on IVF-ET Outcomes in PCOS With Simple Endometrial Hyperplasia

  • Original Article
  • Published:
Reproductive Sciences Aims and scope Submit manuscript

Abstract

Objective

This study investigated the in vitro fertilization (IVF) outcome of levonorgestrel-releasing intrauterine system (LNG-IUS) pretreatment for simple endometrial hyperplasia (EH) in patients with polycystic ovary syndrome (PCOS) undergoing IVF embryo transfer (IVF-ET).

Methods

One hundred ninety patients with PCOS and simple EH without cytologic atypia were allocated randomly to 2 independent arms, that is, the LNG-IUS group (90 patients) and the non-LNG-IUS group (100 patients). Four hundred fourteen patients with PCOS without endometrial disease comprised the control group. Each patient was reevaluated by transvaginal ultrasonography (TVS) and endometrial biopsy after 6 months. For each patient, IVF outcome measures, such as number of recombinant follicle-stimulating hormone, endometrial thickness on human chorionic gonadotropin (HCG) day, hormone levels (progesterone, luetinizing hormone, and serum estradiol) on HCG day, number of oocytes, fertilization rate, clinical pregnancy rate, and miscarriage rate were compared among the 3 groups.

Results

In general, the 3 groups did not differ with respect to the main clinical and biochemical data. After 6 months, patients in LNG-IUS group had an EH resolution rate of 87.77%. In the non-LNG-IUS group, the resolution rate was 15.00%, and 3% of these patients showed progression of EH. The clinical pregnancy rates in the non-LNG-IUS group were significantly lower (28.04%) than that in the LNG-IUS group (46.06%) and the control group (44.65%). The miscarriage rate was highest in the non-LNG-IUS group, but no significant difference in miscarriage rate existed among the 3 groups.

Conclusion

The study illustrates that the LNG-IUS can be safely used for 6 months as a treatment for patients with PCOS and simple EH. Additionally, use of the LNG-IUS can increase the clinical pregnancy rates and implantation rates of patients with PCOS and simple EH who undergo gonadotropin-releasing hormone agonist IVF-ET protocols.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Nandi A, Chen Z, Patel R, Poretsky L. Polycystic ovary syndrome. Endocrinol Metab Clin North Am. 2014;43(1):123–147.

    Article  PubMed  Google Scholar 

  2. Qiao J, Wang L, Li R, Zhang X. Microarray evaluation of endometrial receptivity in Chinese women with polycystic ovary syndrome. Reprod Biomed Online. 2008;17(3):425–435.

    Article  CAS  PubMed  Google Scholar 

  3. Cakmak H, Taylor HS. Human implantation failure: molecular mechanisms and clinical treatment. Hum Reprod Update. 2011; 17(2):242–253.

    Article  CAS  PubMed  Google Scholar 

  4. Panidis D, Tziomalos K, Papadakis E, Katsikis I. Infertility treatment in polycystic ovary syndrome: lifestyle interventions, medications and surgery. Front Horm Res. 2013;40:128–141.

    Article  CAS  PubMed  Google Scholar 

  5. Brezina PR, Mensah V, Balen A, et al. J Assist Reprod Genet. Fertility management in the PCOS population: results of a webbased survey at IVF-worldwide.com. J Assist Reprod Genet. 2013;30(9):1169–1174.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Junk SM, Yeap D. Improved implantation and ongoing pregnancy rates after single-embryo transfer with an optimized protocol for in vitro oocyte maturation in women with polycystic ovaries and polycystic ovary syndrome. Fertil Steril. 2012;98(4):888–892.

    Article  PubMed  Google Scholar 

  7. Coughlan C, Yuan X, Nafee T, Yan J, Mariee N, Li TC. The clinical characteristics of women with recurrent implantation failure. J Obstet Gynaecol. 2013;33(5):494–498

    Article  CAS  PubMed  Google Scholar 

  8. Cheung AP. Ultrasound and menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome. Obstet Gynecol. 2001;98(2):325–331.

    CAS  PubMed  Google Scholar 

  9. Park JC, Lim SY, Jang TK, Bae JG, Kim JI, Rhee JH. Endometrial histology and predictable clinical factors for endometrial disease in women with polycystic ovary syndrome. Clin Exp Reprod Med. 2011;38(1):42–46.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of ‘untreated’ hyperplasia in 170 patients. Cancer. 1985;56(2):403–412.

    Article  CAS  PubMed  Google Scholar 

  11. Ip PP, Irving JA, McCluggage WG, Clement PB, Young RH. Papillary proliferation of the endometrium: a clinicopathologic study of 59 cases of simple and complex papillae without cytologic atypia. Am J Surg Pathol. 2013;37(2):167–177.

    Article  PubMed  Google Scholar 

  12. Goncharenko VM, Beniuk VA, Kalenska OV, Demchenko OM, Spivak MY, Bubnov RV. Predictive diagnosis of endometrial hyperplasia and personalized therapeutic strategy in women of fertile age. EPMA J. 2013;4(1):24–36.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Rakha E, Wong SC, Soomro I, et al. Clinical outcome of atypical endometrial hyperplasia diagnosed on an endometrial biopsy: institutional experience and review of literature. Am J Surg Pathol. 2012;36(11):1683–1690.

    Article  PubMed  Google Scholar 

  14. Haimovich S, Checa MA, Mancebo G, Fusté P, Carreras R. Treatment of endometrial hyperplasia without atypia in perimenopausal and postmenopausal women with a levonorgestrel intrauterine device. Menopause. 2008;15(5):1002–1004.

    Article  PubMed  Google Scholar 

  15. Anastasiadis PG, Skaphida PG, Koutlaki NG, Galazios GC, Tsikouras PN, Liberis VA. Descriptive epidemiology of endometrial hyperplasia in patients with abnormal uterine bleeding. Eur J Gynaecol Oncol. 2000;21(2):131–134.

    CAS  PubMed  Google Scholar 

  16. Haoula ZJ, Walker KF, Powell MC. Levonorgestrel intra-uterine system as a treatment option for complex endometrial hyperplasia. Eur J Obstet Gynecol Reprod Biol. 2011;159(1):176–179.

    Article  CAS  PubMed  Google Scholar 

  17. Bese T, Vural A, Ozturk M, et al. The effect of long-term use of progesterone therapy on proliferation and apoptosis in simple endometrial hyperplasia without atypia. Int J Gynecol Cancer. 2006;16(2):809–813.

    Article  CAS  PubMed  Google Scholar 

  18. Gallos ID, Ganesan R, Gupta JK. Prediction of regression and relapse of endometrial hyperplasia with conservative therapy. Obstet Gynecol. 2013;121(6):1165–1171.

    Article  CAS  PubMed  Google Scholar 

  19. Rattanachaiyanont M, Angsuwathana S, Techatrisak K, Tanmahasamut P, Indhavivadhana S, Leerasiri P. Clinical and pathological responses of progestin therapy for non-atypical endometrial hyperplasia: a prospective study. J Obstet Gynaecol Res. 2005; 31(2):98–106.

    Article  PubMed  Google Scholar 

  20. Hurskainen R, Teperi J, Rissanen P, et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA. 2004;291(12):1456–1463.

    Article  CAS  PubMed  Google Scholar 

  21. Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol. 1982;17(6): 529–536.

    Article  CAS  Google Scholar 

  22. Ercan CM, Duru NK, Sakinci M, Alanbay I, Karasahin KE, Baser I. Successful twin pregnancy achieved by assisted reproductive technology in a patient with polycystic ovary syndrome with complex atypical endometrial hyperplasia treated with levonorgestrel-releasing intrauterine system. Gynecol Endocrinol. 2010;26(2): 125–128.

    Article  CAS  PubMed  Google Scholar 

  23. Kristensen SL, Ramlau-Hansen CH, Ernst E, et al. A very large proportion of young Danish women have polycystic ovaries: is a revision of the Rotterdam criteria needed? Hum Reprod. 2010; 25(12):3117–3122.

    Article  CAS  PubMed  Google Scholar 

  24. Sakamoto C. Sonographic criteria of phasic changes in human endometrial tissue. Int J Gynaecol Obstet. 1985;23(1):7–12.

    Article  CAS  PubMed  Google Scholar 

  25. McCormick BA1, Wilburn RD, Thomas MA, Williams DB, Maxwell R, Aubuchon M. Endometrial thickness predicts endometrial hyperplasia in patients with polycystic ovary syndrome. Fertil Steril. 2011;95(8):2625–2627.

    Article  PubMed  Google Scholar 

  26. Espindola D, Kennedy KA, Fischer EG. Management of abnormal uterine bleeding and the pathology of endometrial hyperplasia. Obstet Gynecol Clins N Am. 2007;34(4):717–737.

    Article  Google Scholar 

  27. Moher D, Schultz KF, Altman DG, and CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomised trials. Lancet. 2001; 357(9263):1191–1194.

    Article  CAS  PubMed  Google Scholar 

  28. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999:84(10):3666–3672.

    Article  CAS  PubMed  Google Scholar 

  29. Puissant F, Van Rysselberge M, Barlow P, Deweze J, Leroy F. Embryo scoring as a prognostic tool in IVF treatment. Hum Reprod. 1987;2(8):705–708.

    Article  CAS  PubMed  Google Scholar 

  30. Giudice LC. Endometrium in PCOS: implantation and predisposition to endocrine CA. Best Pract Res Clin Endocrinol Metab. 2006;20(2):235–244.

    Article  CAS  PubMed  Google Scholar 

  31. Pillay OC, Te Fong LF, Crow JC, et al. The association between polycystic ovaries and endometrial cancer. Hum Reprod. 2006; 21(4):924–929.

    Article  CAS  PubMed  Google Scholar 

  32. Yan L, Wang A, Chen L, Shang W, Li M, Zhao Y. Expression of apoptosis-related genes in the endometrium of polycystic ovary syndrome patients during the window of implantation. Gene. 2012;506(2):350–354.

    Article  CAS  PubMed  Google Scholar 

  33. Ozkaya E, Korkmaz V, Ozkaya Y, Tosun A, Küçükozkan T, Bostan H. Ultrasonographic endometrial thickness measurement is predictive for treatment response in simple endometrial hyperplasia without atypia. J Turk Ger Gynecol Assoc. 2013;14(1): 19–22.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Breijer MC1, Peeters JA, Opmeer BC, et al. Capacity of endometrial thickness measurement to diagnose endometrial carcinoma in asymptomatic postmenopausal women: a systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2012; 40(6):621–629.

    Article  CAS  PubMed  Google Scholar 

  35. Tingthanatikul Y, Choktanasiri W, Rochanawutanon M, Weerakeit S. Prevalence and clinical predictors of endometrial hyperplasia in anovulatory women presenting with amenorrhea. Gynecol Endocrinol. 2006;22(2):101–105.

    Article  PubMed  Google Scholar 

  36. Gruboeck K, Jurkovic D, Lawton F, Savvas M, Tailor A, Campbell S. The diagnostic value of endometrial thickness and volume measurements by three-dimensional ultrasound in patients with postmenopausal bleeding. Ultrasound Obstet Gynecol. 1996; 8(4):272–276.

    Article  CAS  PubMed  Google Scholar 

  37. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–47.

    Article  Google Scholar 

  38. Soliman PT, Oh JC, Schmeler KM, et al. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol. 2005;105(3):575–580.

    Article  PubMed  Google Scholar 

  39. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Onco. 1999;17(6):1736–1744.

    Article  CAS  Google Scholar 

  40. Dhar KK, NeedhiRajan T, Koslowski M, Woolas RP. Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecol Oncol. 2005;97(3):924–927.

    Article  CAS  PubMed  Google Scholar 

  41. Wildemeersch D, Janssens D, Pylyser K, et al. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up. Maturitas. 2007;57(2):210–213.

    Article  CAS  PubMed  Google Scholar 

  42. Orbo A, Arnes M, Hancke C, Vereide AB, Pettersen I, Larsen K. Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. Gynecol Oncol. 2008;111(1):68–73.

    Article  PubMed  Google Scholar 

  43. Varma R, Soneja H, Bhatia K, et al. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia: a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol. 2008;139(2):169–175.

    Article  CAS  PubMed  Google Scholar 

  44. Vereide AB, Kaino T, Sager G, Arnes M, Orbo A. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia. Gynecol Oncol. 2006;101(2):214–223.

    Article  CAS  PubMed  Google Scholar 

  45. Vereide AB, Arnes M, Straume B, Maltau JM, Orbo A. Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol. 2003;91(3):526–533.

    Article  CAS  PubMed  Google Scholar 

  46. Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol (Oxf). 1982;17(6):529–536.

    Article  CAS  Google Scholar 

  47. Orbo A, Vereide A, Arnes M, Pettersen I, Straume B. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial. BJOG. 2014;121(4):477–486.

    Article  CAS  PubMed  Google Scholar 

  48. Karimi-Zarchi M, Dehghani-Firoozabadi R, Tabatabaie A, et al. A comparison of the effect of levonorgestrel IUD with oral medroxyprogesterone acetate on abnormal uterine bleeding with simple endometrial hyperplasia and fertility preservation. Clin Exp Obstet Gynecol. 2013;40(3):421–424.

    CAS  PubMed  Google Scholar 

  49. Chen SL, Wu FR, Luo C, Chen X, Shi XY, Zheng HY. Combined analysis of endometrial thickness and pattern in predicting outcome of in vitro fertilization and embryo transfer: a retrospective cohort study. Reprod Biol Endocrinol. 2010,8(1):30–37.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  50. Traub ML, Arsdale AV, Pal L, Jindal S, Santoro N. Endometrial thickness, Caucasian ethnicity, and age predict clinical pregnancy following fresh blastocyst embryo transfer: a retrospective cohort. Reprod Biol Endocrinol. 2009;7(1):33–40.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Detti L, Yelian FD, Kruger ML, Diamond MP, Rode A, Mitwally MFM. Endometrial thickness is related to miscarriage rate, but not the estradiol concentration, in cycles down-regulated with gonadotropin-releasing hormone antagonist. Fertil Steril. 2008; 89(4):998–1001.

    Article  CAS  PubMed  Google Scholar 

  52. Isaacs JD Jr, Wells CS, Williams DB, Odem RR, Gast MJ, Stickler RC. Endometrial thickness is a valid monitoring parameter in cycles of ovulation induction with menotropins alone. Fertil Steril. 1996;65(2):262–266.

    Article  PubMed  Google Scholar 

  53. Weissman A, Gotlieb L, Casper RF. The detrimental effect of increased endometrial thickness on implantation and pregnancy rates and outcome in an in vitro fertilization program. Fertil Steril. 1999;71(1):147–149.

    Article  CAS  PubMed  Google Scholar 

  54. Ke RW. Endocrine basis for recurrent pregnancy loss. Obstet Gynecol Clin North Am. 2014;41(1):103–112.

    Article  PubMed  Google Scholar 

  55. Palomba S, Falbo A, La Sala GB. Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. BJOG. 2013;120(3):267–276.

    Article  CAS  PubMed  Google Scholar 

  56. Siristatidis CS, Maheshwari A, Bhattacharya S. In vitro maturation in sub fertile women with polycystic ovarian syndrome under-going assisted reproduction. Cochrane Database Syst Rev. 2009;(1):CD006606.

    Google Scholar 

  57. Griesinger G, Diedrich K, Tarlatzis BC, Kolibianakis EM. GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod Biomed Online. 2006;13(5):628–638.

    Article  CAS  PubMed  Google Scholar 

  58. MacDougall MJ, Tan SL, Balen A, Jacobs HS. A controlled study comparing patients with and without polycystic ovaries undergoing in-vitro fertilization. Hum Reprod. 1993;8(2):233–237.

    Article  CAS  PubMed  Google Scholar 

  59. Daya S. Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles. Cochrane Database Syst Rev. 2000;(2): CD001299.

    Google Scholar 

  60. Conn PM, Staley D, Harris C, Andrews WV, Gorospe WC, McArdle CA. Mechanism of action of gonadotropin releasing hormone. Annu Rev Physiol. 1986;48(3):495–513.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, The Shanghai Jiaotong University Affiliated Sixth People’s Hospital, 600 Yishan, Road, 200233, Shanghai, China

    Jiang Bian PhD, Hongfang Shao MD, Lu Fang MD, Changying Xing PhD, Lihong Wang PhD & Minfang Tao PhD

  2. Department of Obstetrics and Gynecology, Jingzhou Central Hospital, Jingzhou, China

    Jiang Bian PhD, Hua Liu MD & Hui Li MD

Authors
  1. Jiang Bian PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hongfang Shao MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hua Liu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hui Li MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lu Fang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Changying Xing PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lihong Wang PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Minfang Tao PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Minfang Tao PhD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bian, J., Shao, H., Liu, H. et al. Efficacy of the Levonorgestrel-Releasing Intrauterine System on IVF-ET Outcomes in PCOS With Simple Endometrial Hyperplasia. Reprod. Sci. 22, 758–766 (2015). https://doi.org/10.1177/1933719114561553

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/1933719114561553

Keywords

Search

Navigation